Fairvalue-Calculator Fairvalue-Calculator
EN DE

Amarin Corporation (AMRN) Fair Value & Analysis

Healthcare · US · Market cap $331M

Price$15.97
Fair Value$20.91
Upside+30.9%
Quality95/100
Evidence: Medium Range $13.80 – $26.13

Fair value as of: Jun 24, 2026

Analysis

Amarin Corporation (AMRN) currently trades at $15.97, while our model-based Fair Value estimate is $20.91 — implying the stock looks roughly 30.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -29% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% Merck & Co (MRCK34) -35% AstraZeneca PLC (A1ZN34) -31%

Frequently asked questions

Is Amarin Corporation (AMRN) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $20.91 versus a price of $15.97 — about +31% (undervalued). Model-based estimate, not financial advice.
What is the fair value of AMRN?
Our 21-model fair value for Amarin Corporation is $20.91 (as of Jun 24, 2026), built from audited fundamentals. The current price is $15.97.
What is the quality score of AMRN?
Amarin Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.